About Us
Contact Us
Yongzhong Wang,Ph.D,Executive Vice President
Dr. Yongzhong Wang manages manufacturing, API sales, international regulatory affairs, and Simcere Europe. Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China.

Dr. Wang was instrumental for the development and commercialization of Conbercept, a fusion protein approved in 2013 in China as the longest lasting wAMD drug in the world. As CEO, he led the company to achieve triple digit growth and transitioned the previously single product-centric company to a full-fledged biotech business covering integrated R&D of multiple products, commercial manufacturing & distribution, and international development. In 2016, he successfully led his team to open a FDA IND for Conbercept to bypass Phases 1&2 and directly enter Phase 3 in the US, a rarity for novel biologics originally developed outside the US and the first for China. Prior to Kanghong Biotech, Dr. Wang worked at Genzyme in Cambridge, MA, where he led critical projects for a number of innovative products including MACI, the first tissue engineering product approved by the FDA for adult cartilage repair. While at Genzyme, Dr. Wang had two US/PCT patents and supported international marketing. Dr. Wang earned his Ph.D at Tufts University and had 10 peer reviewed publications with totally over 3000 citations.
© Copyright 2016 www.simcere.com All Rights Reserved.